Catalent Scientist Presents Bioavailability Solutions At 7th Annual Improving Solubility Summit
Somerset, NJ, June 23, 2011 —Julien Meissonnier, Director of Research and Development for Catalent Pharma Solutions, will present “Enhancing the Bioavailability of Poorly Water-Soluble Drugs: Oral Lipid-Based Formulations” at the 7th Annual Improving Solubility Summit in London, UK, June 28-30, 2011. The conference will include the latest techniques, technologies and solutions to implement development strategies for poorly water soluble drug candidates.
Mr. Meissonnier will present on Tuesday, June 28 at 2:00 p.m. GMT alongside lipid based drug delivery systems expert René Holm, Head of Preformulation, Lundbeck. The presentation will focus on commercially proven drug delivery solutions that solve both solubility and bioavailability issues of new chemical entities. Mr. Meissonnier will provide insights based on his in-depth knowledge of industrial obstacles related to stability and absorption that limit the use of lipid-based formulations and highlight emerging solutions, such as softgel technologies, that overcome these obstacles and improve performance. He will also share expert considerations and perspectives for the future of oral lipid-based formulations.
“Bioavailability and solubility challenges are a major concern in today’s marketplace, especially as researchers seek to develop oral formulation methods for new chemical entities derived from macromolecules,” said Mr. Meissonnier. “The 7th Annual Improving Solubility Summit addresses the core of this industrial obstacle and today’s presentation offers a unique opportunity to demonstrate Catalent’s innovative capabilities and softgel technologies that solve this growing industry issue.”
With 13 years of experience in pharmaceutical development, Mr. Meissonnier leads Catalent’s European centre of excellence for the development of lipid-based drug delivery solutions. He provides technical and scientific leadership for the development of poorly soluble drugs that lead to approvable regulatory dossiers. Mr. Meissonnier received his Engineer Degree in Physico-Chemistry from the ISMRa in Caen, France. He is an expert in his field and currently sits on the Board of Directors with the Alsace Biovalley life sciences and healthcare cluster based in France. As a board member, he supports Alsace BioValley in its efforts to continue driving growth in the life sciences by identifying and coordinating ambitious projects that will create employment opportunities in the region.
For a follow-up interview with Mr. Meissonnier, please contact Patricia McGee at firstname.lastname@example.org .
To learn more about Mr. Meissonnier, please visit www.catalent.com .
For more information on the 7th Annual Improving Solubility Summit, please visit www.improvingsolubility.co.uk .
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.